Talquetamab with iberdomide for relapsed or refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new combination of three drugs: talquetamab (a bispecific antibody), iberdomide (a pill), and dexamethasone (a steroid) for people with multiple myeloma that has returned or become resistant after other treatments. The goal is to see if this triplet is safe and effective at shrinking the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your multiple myeloma has come back or is not responding to at least 3 prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and a CD38 antibody
- You have measurable myeloma protein in your blood or urine
- You are able to care for yourself (ECOG score 0 or 1)
- Your kidneys, liver, and blood cell counts are within safe ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two drugs, talquetamab and lenalidomide, as maintenance therapy after a stem cell transplant for multiple myeloma. The goal is to see if this combination helps keep the cancer from coming back.
This trial tests a new combination of two drugs (teclistamab and iberdomide) for people with multiple myeloma that has come back or stopped responding to standard treatments. The goal is to see how well this combination works and whether it can help control the disease.
This trial tests two new medicines, talquetamab and belantamab mafodotin, for people whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if this combination can shrink the cancer and help you feel better.
This study looks at how well two newer medicines, teclistamab and talquetamab, work in people with multiple myeloma that has come back or stopped responding to several treatments. If you qualify, you may be able to receive one of these medicines as part of your regular care.
This Phase 2 trial tests two antibody medicines (teclistamab or talquetamab) given as outpatient injections, to treat multiple myeloma. It also tests preventing and treating side effects with supportive medicines, aiming to improve disease control in people who have already tried other myeloma treatments.
This study tests a drug called talquetamab for people with multiple myeloma who have already had a type of immunotherapy called CAR T-cell therapy (ide-cel). The goal is to see if talquetamab can help control the cancer after the CAR T cells have had time to work.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.